ReviewMedScience2026
Innovative analysis and future prospects of Bupleuri Radix's pharmacology and toxicity based on the gut-liver axis.
Review in MedScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bupleuri Radix (BR) is a traditional Chinese medicine, which has a significant protective effect on hepatic and intestinal diseases, but its potential hepatotoxicity is still worrying. The bi-directional effects of BR are systematically summarized in this review, with a primary focus on the gut-liver axis. Saikosaponins, as the main bioactive components of BR, are converted by the gut microbiota into metabolites with enhanced bioavailability, thereby regulating the intestinal flora, strengthening the intestinal barrier, and alleviating inflammation through pathways such as NF-κB, PI3K/Akt/mTOR, and STAT3. Concurrently, BR and its components exert hepatoprotective effects through antioxidant, anti-inflammatory, and metabolic regulation mechanisms. However, saikosaponin and volatile oil may induce hepatotoxicity via oxidative stress and apoptosis. Critical evidence gaps persist regarding the systematic interplay between BR's multi-component actions and the gut-liver axis, the toxicity of metabolites, and clinical hepatotoxicity risk. Future research should prioritize these areas to optimize the safe and effective application of BR.
Indexed as
Identifiers
42228039What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.